BioSpace News Archive

Approval Supported by Data from Phase 3 Head-to-Head Study vs. Gefitinib

Shionogi & Co., Ltd. announced today that 14 presentations will feature the company’s investigational compounds at IDWeek™ 2018, in San Francisco, October 3-7, 2018.

Market Leader in Radar Sensors Recognized by DHS for Innovative Applications

PharmaCyte Biotech, Inc. today announced that it has successfully completed a study to determine the best assay method for the accurate determination of the number of viable encapsulated cells at any given time inside PharmaCyte’s Cell-in-a Box® capsules

Recros Medica, Inc. will unveil the Nuvellus™ brand at this week’s American Society of Plastic Surgery meeting.

Velos is empowering its customers to take their clinical research productivity, automation, and integration to the next level with a powerful new web services layer.

BioUtah today announced that the board of directors has selected Kelvyn H. Cullimore Jr. as its president and CEO. Cullimore will succeed Kelly Slone, who has served in that capacity for the past three years.

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”), is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, today congratulates the Ontario government for introducing legislation that would open up recreational cannabis retail to the private sector.

NEJM Group announced Thursday that Jeffrey M. Drazen, M.D., Editor-in-Chief of the New England Journal of Medicine, will retire within the next year.

Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced topline positive safety and efficacy data from the second dose cohort and positive longer-term data from the first dose cohort of the ongoing Phase 1/2 study of DTX301.